Our study provides novel insights into the evolving non-genetic landscape of osimertinib resistance in EGFR-mutant NSCLC, establishing AP-1 transcription factor as a targetable determinant of state-specific hallmarks, offering therapeutic potential to reinstate drug sensitivity. This evidence concerns the gene EGFR and non-small cell lung carcinoma.